title: Obinutuzumab for chronic lymphocytic leukemia.
abstract: Chronic lymphocytic leukemia (CLL) is a frequent hematological malignancy that is incurable using standard approaches. Two anti-CD20 monoclonal antibodies (mAb), rituximab and ofatumumab, have been approved for CLL treatment. A new glycoengineered type II humanized anti-CD20 mAb, obinutuzumab (GA101), has been developed and demonstrates increased activity against B-cell malignancies by inducing direct cell death and better antibody-dependent cellular cytotoxicity. In a recent randomized Phase III study in patients with newly diagnosed CLL and coexisting conditions, obinutuzumab plus chlorambucil demonstrated significant improvement in progression-free survival and several other outcome parameters, in contrast to rituximab plus chlorambucil. Grade 3-4 infusion-related reactions and neutropenia occurred more frequently in patients who received obinutuzumab compared with those who received rituximab; however, the rate of serious infections was similar. Obinutuzumab represents a promising new option for patients with CLL and must be investigated with other chemotherapy regimens or with new targeted agents.
authors.affiliation: Hospices Civils de Lyon, Unité de Pharmacie Clinique Oncologique, Université de Lyon - EMR 3738, Pierre-Bénite, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Rioufol
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology / Q000378:metabolism; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002699:Chlorambucil / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006207:Half-Life; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D009503:Neutropenia / Q000209:etiology; D015202:Protein Engineering; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D002699:Chlorambucil; D000069283:Rituximab; C543332:obinutuzumab
keywords: anti-CD20 monoclonal antibody; antibody-dependent cellular cytotoxicity; chlorambucil; chronic lymphocytic leukemia; direct cell death; infusion-related reaction; obinutuzumab; rituximab